HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt At '2.0' On Consumer Expansion But Question No. 1 Remains, Potential Pfizer Business Bid?

This article was originally published in The Pink Sheet

Executive Summary

UK firm sees acquisitions of Mead Johnson Nutrition and the Schiff brand as major milestones in its trajectory as a consumer health market competitor, but market analysts say both would be rendered comparatively minor moves if it makes an offer to acquire Pfizer's consumer products business.

You may also be interested in...



Pfizer Mum On Consumer Business Plans As Analysts Say Spin-off

Pfizer continues to review options for its consumer business, though analysts say a spin-off makes most sense. During its fourth-quarter earnings call, firm reported the division's US sales slumped 9% but 12% growth in international markets buoyed the worldwide results.

Schiff Supplements, MJN Formulas, Other Reckitt Benckiser Consumer Brands Get Their Own Home

UK manufacturer in January begins operating with a separate health care division, representing 60% of sales with products including Schiff supplements and Mead Johnson infant and adult formulas, and a home care/hygiene division led by Lysol disinfectants. The plan piques analysts' expectations that operating the divisions separately will lead to divesting one.

RB Says Petya Cyberattack Froze Shipments, Could Cost £100M

Beiersdorf and Merck also were impacted by the June 27 malware attack that rocked the globe, but RB's the only one of the three that's in any way quantified the hit it sustained. The blow comes at an unfortunate time for the UK-based company, whose first-quarter performance was its weakest in 15 years.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel